In recent years guidelines for the treatment of type 2 diabetes (T2DM) have evolved substantially. Initially limited to a few glucose lowering agents, early guidelines predicated strict glycemic control as a main goal in the attempt to reduce the risk of long-term diabetic complications. Nowadays, guidelines are not limited to such a goal but include cardiovascular (and renal) protection. This rapid evolution was made possible by the introduction of new glucose lowering agents, which have been extensively tested in randomized clinical studies including large cardiovascular outcome trials (CVOTs). In this review we will specifically consider the use of incretin-based medications in T2DM as recommended in the recent ADA/EASD consensus, and other international guidelines, with special consideration of their glucose-lowering efficacy, their cardiovascular (and renal) benefit, their effect on body weight and risk of hypoglycemia, as well as the economic implications for their use.

中文翻译：

---

使用基于肠降血糖素的药物：关于GLP-1受体激动剂和DPP-4抑制剂，当前的国际建议如何建议？

近年来，治疗2型糖尿病（T2DM）的指南已得到实质性发展。最初仅限于几种降糖药，早期指南将严格的血糖控制作为降低长期糖尿病并发症风险的主要目标。如今，指南不仅限于此目标，还包括心血管（和肾脏）保护。引入新的降糖药使这种快速发展成为可能，这些药物已在包括大型心血管结果试验（CVOT）在内的随机临床研究中得到了广泛测试。在本次审查中，我们将特别考虑根据最近的ADA / EASD共识和其他国际指南的建议，在T2DM中使用基于肠降血糖素的药物，并特别考虑其降糖功效，